1-3 of 3
J. Carl Barrett, PhD
Close
Sort by
Journal Articles

Development and Use of Clinical Pharmacodynamic Assays to Demonstrate Target Engagement for AZD4573, a Selective and Potent CDK9 Inhibitor Currently in Phase I Clinical Trials

Tammie Yeh, PhD, Greg O'Connor, MS, Justin Cidado, PhD, J. Carl Barrett, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3505.
https://doi.org/10.1182/blood-2018-99-114948
Published: 2018
Journal Articles

Preclinical and Clinical Pharmacodynamics of Pan-Pim Inhibition By AZD1208 in Acute Myeloid Leukemia: Assessment of Pim Isoform Dependency for Bad and 4EBP1 Phosphorylation

Kristen A McEachern, PhD, Adriana E Tron, PhD, Greg O'Connor, Rachel DuPont, Francis D Gibbons, PhD, Lourdes Pablo, Karthick Vishwanathan, PhD, Patricia McCoon, PhD, Jorge E. Cortes, MD, Daniel J. DeAngelo, MDPhD, Mark D Minden, MDPhD, Geoffrey L. Uy, MD, Frank Neumann, MDPhD, Karen Keating, Dennis Huszar, PhD, J. Elizabeth Pease, PhD, Jeffrey Brown, PhD, J. Carl Barrett, PhD
Journal: Blood
Blood (2014) 124 (21): 906.
https://doi.org/10.1182/blood.V124.21.906.906
Published: 2014
Journal Articles

Mathematical Simulation of BCR-ABL Real Time Quantitative Polymerase Chain Reaction (RQ-PCR) for Chronic Myeloid Leukemia (CML) Response Monitoring Provides Insight on the Basis of International Standardization.

Vi j ay Modur, MD, PhD, Dean C Bottino, PhD, Susan Branford, PhD, Tillmann Krahnke, PhD, Fabrizio Pane, MD, Marc Rudoltz, MD, Yu Jin, Timothy P Hughes, MD, Dong-Wook Kim, MD, PhD, Jerald Radich, MD, J. Carl Barrett, PhD
Journal: Blood
Blood (2008) 112 (11): 2124.
https://doi.org/10.1182/blood.V112.11.2124.2124
Published: 2008